APO Research
Talk to an analyst

APO RESEARCH · REPORT

Afatinib Dimaleate

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Afatinib Dimaleate Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026196 pages

Choose your research edition.

Industry ResearchAfatinib Dimaleate Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Afatinib Dimaleate Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Afatinib Dimaleate Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Afatinib Dimaleate Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Afatinib Dimaleate Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Afatinib Dimaleate market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Afatinib Dimaleate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Afatinib Dimaleate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Afatinib Dimaleate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Afatinib Dimaleate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Afatinib Dimaleate include Boehringer-Ingelheim, Beacon Pharmaceuticals, Hansoh Pharmaceuticak, Kelun－Kazpharm, Merck, Qilu Pharmaceutical, Qingfeng Medicine Group, CSPC Pharmaceutical and Yangtze River Pharm, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Afatinib Dimaleate market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Afatinib Dimaleate and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Afatinib Dimaleate sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Afatinib Dimaleate market size, projected growth trends, production technologies, key applications, and end-use industries.

Afatinib Dimaleate Segment by Company

Boehringer-Ingelheim

Beacon Pharmaceuticals

Hansoh Pharmaceuticak

Kelun－Kazpharm

Merck

Qilu Pharmaceutical

Qingfeng Medicine Group

CSPC Pharmaceutical

Yangtze River Pharm

Chia Tai-Tianqing

Afatinib Dimaleate Segment by Type

20 mg

30 mg

40 mg

Afatinib Dimaleate Segment by Application

Hospital

Clinic

Afatinib Dimaleate Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Afatinib Dimaleate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Afatinib Dimaleate and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Afatinib Dimaleate.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Afatinib Dimaleate market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Afatinib Dimaleate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Afatinib Dimaleate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Afatinib Dimaleate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Afatinib Dimaleate Industry Trends Table 2. Afatinib Dimaleate Industry Drivers Table 3. Afatinib Dimaleate Industry Opportunities and Challenges Table 4. Afatinib Dimaleate Industry Restraints Table 5. Global Afatinib Dimaleate Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Afatinib Dimaleate Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Afatinib Dimaleate Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Afatinib Dimaleate Sales Market Share by Manufacturers Table 9. Global Afatinib Dimaleate Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Afatinib Dimaleate Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Afatinib Dimaleate Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Afatinib Dimaleate Manufacturers, Product Type & Application Table 13. Global Afatinib Dimaleate Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Afatinib Dimaleate by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 20 mg Table 17. Major Manufacturers of 30 mg Table 18. Major Manufacturers of 40 mg Table 19. Global Afatinib Dimaleate Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Afatinib Dimaleate Sales by Type (2021-2026) & (K Units) Table 21. Global Afatinib Dimaleate Sales by Type (2027-2032) & (K Units) Table 22. Global Afatinib Dimaleate Sales Market Share by Type (2021-2026) Table 23. Global Afatinib Dimaleate Sales Market Share by Type (2027-2032) Table 24. Global Afatinib Dimaleate Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Afatinib Dimaleate Revenue by Type (2021-2026) & (K Units) Table 26. Global Afatinib Dimaleate Revenue by Type (2027-2032) & (K Units) Table 27. Global Afatinib Dimaleate Revenue Market Share by Type (2021-2026) Table 28. Global Afatinib Dimaleate Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Table 30. Major Manufacturers of Clinic Table 31. Global Afatinib Dimaleate Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Afatinib Dimaleate Sales by Application (2021-2026) & (K Units) Table 33. Global Afatinib Dimaleate Sales by Application (2027-2032) & (K Units) Table 34. Global Afatinib Dimaleate Sales Market Share by Application (2021-2026) Table 35. Global Afatinib Dimaleate Sales Market Share by Application (2027-2032) Table 36. Global Afatinib Dimaleate Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Afatinib Dimaleate Revenue by Application (2021-2026) & (K Units) Table 38. Global Afatinib Dimaleate Revenue by Application (2027-2032) & (K Units) Table 39. Global Afatinib Dimaleate Revenue Market Share by Application (2021-2026) Table 40. Global Afatinib Dimaleate Revenue Market Share by Application (2027-2032) Table 41. Global Afatinib Dimaleate Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Afatinib Dimaleate Sales by Region (2021-2026) & (K Units) Table 43. Global Afatinib Dimaleate Sales Market Share by Region (2021-2026) Table 44. Global Afatinib Dimaleate Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Afatinib Dimaleate Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Afatinib Dimaleate Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Afatinib Dimaleate Sales by Country (2021-2026) & (K Units) Table 48. North America Afatinib Dimaleate Sales by Country (2027-2032) & (K Units) Table 49. Europe Afatinib Dimaleate Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Afatinib Dimaleate Sales by Country (2021-2026) & (K Units) Table 51. Europe Afatinib Dimaleate Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Afatinib Dimaleate Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Afatinib Dimaleate Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Afatinib Dimaleate Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Afatinib Dimaleate Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Afatinib Dimaleate Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Afatinib Dimaleate Sales by Country (2027-2032) & (K Units) Table 58. Global Afatinib Dimaleate Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Afatinib Dimaleate Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Afatinib Dimaleate Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Afatinib Dimaleate Revenue Market Share by Region (2021-2026) Table 62. Global Afatinib Dimaleate Revenue Market Share by Region (2027-2032) Table 63. Boehringer-Ingelheim Company Information Table 64. Boehringer-Ingelheim Business Overview Table 65. Boehringer-Ingelheim Afatinib Dimaleate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Boehringer-Ingelheim Afatinib Dimaleate Product Portfolio Table 67. Boehringer-Ingelheim Recent Development Table 68. Beacon Pharmaceuticals Company Information Table 69. Beacon Pharmaceuticals Business Overview Table 70. Beacon Pharmaceuticals Afatinib Dimaleate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Beacon Pharmaceuticals Afatinib Dimaleate Product Portfolio Table 72. Beacon Pharmaceuticals Recent Development Table 73. Hansoh Pharmaceuticak Company Information Table 74. Hansoh Pharmaceuticak Business Overview Table 75. Hansoh Pharmaceuticak Afatinib Dimaleate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Hansoh Pharmaceuticak Afatinib Dimaleate Product Portfolio Table 77. Hansoh Pharmaceuticak Recent Development Table 78. Kelun－Kazpharm Company Information Table 79. Kelun－Kazpharm Business Overview Table 80. Kelun－Kazpharm Afatinib Dimaleate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Kelun－Kazpharm Afatinib Dimaleate Product Portfolio Table 82. Kelun－Kazpharm Recent Development Table 83. Merck Company Information Table 84. Merck Business Overview Table 85. Merck Afatinib Dimaleate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Merck Afatinib Dimaleate Product Portfolio Table 87. Merck Recent Development Table 88. Qilu Pharmaceutical Company Information Table 89. Qilu Pharmaceutical Business Overview Table 90. Qilu Pharmaceutical Afatinib Dimaleate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Qilu Pharmaceutical Afatinib Dimaleate Product Portfolio Table 92. Qilu Pharmaceutical Recent Development Table 93. Qingfeng Medicine Group Company Information Table 94. Qingfeng Medicine Group Business Overview Table 95. Qingfeng Medicine Group Afatinib Dimaleate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Qingfeng Medicine Group Afatinib Dimaleate Product Portfolio Table 97. Qingfeng Medicine Group Recent Development Table 98. CSPC Pharmaceutical Company Information Table 99. CSPC Pharmaceutical Business Overview Table 100. CSPC Pharmaceutical Afatinib Dimaleate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. CSPC Pharmaceutical Afatinib Dimaleate Product Portfolio Table 102. CSPC Pharmaceutical Recent Development Table 103. Yangtze River Pharm Company Information Table 104. Yangtze River Pharm Business Overview Table 105. Yangtze River Pharm Afatinib Dimaleate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Yangtze River Pharm Afatinib Dimaleate Product Portfolio Table 107. Yangtze River Pharm Recent Development Table 108. Chia Tai-Tianqing Company Information Table 109. Chia Tai-Tianqing Business Overview Table 110. Chia Tai-Tianqing Afatinib Dimaleate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Chia Tai-Tianqing Afatinib Dimaleate Product Portfolio Table 112. Chia Tai-Tianqing Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Afatinib Dimaleate Distributors List Table 116. Afatinib Dimaleate Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Afatinib Dimaleate Product Image Figure 2. Global Afatinib Dimaleate Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Afatinib Dimaleate Market Size (2021-2032) & (US$ Million) Figure 4. Global Afatinib Dimaleate Sales (2021-2032) & (K Units) Figure 5. Global Afatinib Dimaleate Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Afatinib Dimaleate Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 20 mg Image Figure 9. 30 mg Image Figure 10. 40 mg Image Figure 11. Global Afatinib Dimaleate Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Afatinib Dimaleate Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Afatinib Dimaleate Sales Market Share by Type (2021-2032) Figure 14. Global Afatinib Dimaleate Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Afatinib Dimaleate Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Afatinib Dimaleate Revenue Market Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Afatinib Dimaleate Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Afatinib Dimaleate Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Afatinib Dimaleate Sales Market Share by Application (2021-2032) Figure 22. Global Afatinib Dimaleate Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Afatinib Dimaleate Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Afatinib Dimaleate Revenue Market Share by Application (2021-2032) Figure 25. North America Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Afatinib Dimaleate Sales Market Share by Country (2021-2032) Figure 27. U.S. Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Afatinib Dimaleate Sales Market Share by Country (2021-2032) Figure 32. Germany Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Afatinib Dimaleate Sales Market Share by Country (2021-2032) Figure 39. China Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Afatinib Dimaleate Sales Market Share by Country (2021-2032) Figure 47. Brazil Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Afatinib Dimaleate Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Afatinib Dimaleate Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Afatinib Dimaleate Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Afatinib Dimaleate Revenue (2021-2032) & (US$ Million) Figure 58. North America Afatinib Dimaleate Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Afatinib Dimaleate Revenue (2021-2032) & (US$ Million) Figure 60. Europe Afatinib Dimaleate Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Afatinib Dimaleate Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Afatinib Dimaleate Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Afatinib Dimaleate Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Afatinib Dimaleate Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Afatinib Dimaleate Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Afatinib Dimaleate Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • 20 mg
  • 30 mg
  • 40 mg
Applications
  • Hospital
  • Clinic
Companies covered
  • Boehringer-Ingelheim
  • Beacon Pharmaceuticals
  • Hansoh Pharmaceuticak
  • Kelun－Kazpharm
  • Merck
  • Qilu Pharmaceutical
  • Qingfeng Medicine Group
  • CSPC Pharmaceutical
  • Yangtze River Pharm
  • Chia Tai-Tianqing

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Afatinib Dimaleate Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Afatinib Dimaleate Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Afatinib Dimaleate Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Afatinib Dimaleate Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Afatinib Dimaleate Market Dynamics
  1. 2.1 Afatinib Dimaleate Industry Trends
  2. 2.2 Afatinib Dimaleate Industry Drivers
  3. 2.3 Afatinib Dimaleate Industry Opportunities and Challenges
  4. 2.4 Afatinib Dimaleate Industry Restraints
3 Afatinib Dimaleate Market by Manufacturers
  1. 3.1 Global Afatinib Dimaleate Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Afatinib Dimaleate Sales by Manufacturers (2021-2026)
  3. 3.3 Global Afatinib Dimaleate Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Afatinib Dimaleate Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Afatinib Dimaleate Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Afatinib Dimaleate Manufacturers, Product Type & Application
  7. 3.7 Global Afatinib Dimaleate Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Afatinib Dimaleate Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Afatinib Dimaleate Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Afatinib Dimaleate Tier 1, Tier 2, and Tier 3
4 Afatinib Dimaleate Market by Type
  1. 4.1 Afatinib Dimaleate Type Introduction
  2. 4.1.1 20 mg
  3. 4.1.2 30 mg
  4. 4.1.3 40 mg
  5. 4.2 Global Afatinib Dimaleate Sales by Type
  6. 4.2.1 Global Afatinib Dimaleate Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Afatinib Dimaleate Sales by Type (2021-2032)
  8. 4.2.3 Global Afatinib Dimaleate Sales Market Share by Type (2021-2032)
  9. 4.3 Global Afatinib Dimaleate Revenue by Type
  10. 4.3.1 Global Afatinib Dimaleate Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Afatinib Dimaleate Revenue by Type (2021-2032)
  12. 4.3.3 Global Afatinib Dimaleate Revenue Market Share by Type (2021-2032)
5 Afatinib Dimaleate Market by Application
  1. 5.1 Afatinib Dimaleate Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Afatinib Dimaleate Sales by Application
  5. 5.2.1 Global Afatinib Dimaleate Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Afatinib Dimaleate Sales by Application (2021-2032)
  7. 5.2.3 Global Afatinib Dimaleate Sales Market Share by Application (2021-2032)
  8. 5.3 Global Afatinib Dimaleate Revenue by Application
  9. 5.3.1 Global Afatinib Dimaleate Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Afatinib Dimaleate Revenue by Application (2021-2032)
  11. 5.3.3 Global Afatinib Dimaleate Revenue Market Share by Application (2021-2032)
6 Global Afatinib Dimaleate Sales by Region
  1. 6.1 Global Afatinib Dimaleate Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Afatinib Dimaleate Sales by Region (2021-2032)
  3. 6.2.1 Global Afatinib Dimaleate Sales by Region (2021-2026)
  4. 6.2.2 Global Afatinib Dimaleate Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Afatinib Dimaleate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Afatinib Dimaleate Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Afatinib Dimaleate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Afatinib Dimaleate Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Afatinib Dimaleate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Afatinib Dimaleate Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Afatinib Dimaleate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Afatinib Dimaleate Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Afatinib Dimaleate Revenue by Region
  1. 7.1 Global Afatinib Dimaleate Revenue by Region
  2. 7.1.1 Global Afatinib Dimaleate Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Afatinib Dimaleate Revenue by Region (2021-2026)
  4. 7.1.3 Global Afatinib Dimaleate Revenue by Region (2027-2032)
  5. 7.1.4 Global Afatinib Dimaleate Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Afatinib Dimaleate Revenue (2021-2032)
  8. 7.2.2 North America Afatinib Dimaleate Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Afatinib Dimaleate Revenue (2021-2032)
  11. 7.3.2 Europe Afatinib Dimaleate Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Afatinib Dimaleate Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Afatinib Dimaleate Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Afatinib Dimaleate Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Afatinib Dimaleate Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Boehringer-Ingelheim
  2. 8.1.1 Boehringer-Ingelheim Company Information
  3. 8.1.2 Boehringer-Ingelheim Business Overview
  4. 8.1.3 Boehringer-Ingelheim Afatinib Dimaleate Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Boehringer-Ingelheim Afatinib Dimaleate Product Portfolio
  6. 8.1.5 Boehringer-Ingelheim Recent Developments
  7. 8.2 Beacon Pharmaceuticals
  8. 8.2.1 Beacon Pharmaceuticals Company Information
  9. 8.2.2 Beacon Pharmaceuticals Business Overview
  10. 8.2.3 Beacon Pharmaceuticals Afatinib Dimaleate Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Beacon Pharmaceuticals Afatinib Dimaleate Product Portfolio
  12. 8.2.5 Beacon Pharmaceuticals Recent Developments
  13. 8.3 Hansoh Pharmaceuticak
  14. 8.3.1 Hansoh Pharmaceuticak Company Information
  15. 8.3.2 Hansoh Pharmaceuticak Business Overview
  16. 8.3.3 Hansoh Pharmaceuticak Afatinib Dimaleate Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Hansoh Pharmaceuticak Afatinib Dimaleate Product Portfolio
  18. 8.3.5 Hansoh Pharmaceuticak Recent Developments
  19. 8.4 Kelun－Kazpharm
  20. 8.4.1 Kelun－Kazpharm Company Information
  21. 8.4.2 Kelun－Kazpharm Business Overview
  22. 8.4.3 Kelun－Kazpharm Afatinib Dimaleate Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Kelun－Kazpharm Afatinib Dimaleate Product Portfolio
  24. 8.4.5 Kelun－Kazpharm Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Afatinib Dimaleate Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck Afatinib Dimaleate Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Qilu Pharmaceutical
  32. 8.6.1 Qilu Pharmaceutical Company Information
  33. 8.6.2 Qilu Pharmaceutical Business Overview
  34. 8.6.3 Qilu Pharmaceutical Afatinib Dimaleate Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Qilu Pharmaceutical Afatinib Dimaleate Product Portfolio
  36. 8.6.5 Qilu Pharmaceutical Recent Developments
  37. 8.7 Qingfeng Medicine Group
  38. 8.7.1 Qingfeng Medicine Group Company Information
  39. 8.7.2 Qingfeng Medicine Group Business Overview
  40. 8.7.3 Qingfeng Medicine Group Afatinib Dimaleate Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Qingfeng Medicine Group Afatinib Dimaleate Product Portfolio
  42. 8.7.5 Qingfeng Medicine Group Recent Developments
  43. 8.8 CSPC Pharmaceutical
  44. 8.8.1 CSPC Pharmaceutical Company Information
  45. 8.8.2 CSPC Pharmaceutical Business Overview
  46. 8.8.3 CSPC Pharmaceutical Afatinib Dimaleate Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 CSPC Pharmaceutical Afatinib Dimaleate Product Portfolio
  48. 8.8.5 CSPC Pharmaceutical Recent Developments
  49. 8.9 Yangtze River Pharm
  50. 8.9.1 Yangtze River Pharm Company Information
  51. 8.9.2 Yangtze River Pharm Business Overview
  52. 8.9.3 Yangtze River Pharm Afatinib Dimaleate Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Yangtze River Pharm Afatinib Dimaleate Product Portfolio
  54. 8.9.5 Yangtze River Pharm Recent Developments
  55. 8.10 Chia Tai-Tianqing
  56. 8.10.1 Chia Tai-Tianqing Company Information
  57. 8.10.2 Chia Tai-Tianqing Business Overview
  58. 8.10.3 Chia Tai-Tianqing Afatinib Dimaleate Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Chia Tai-Tianqing Afatinib Dimaleate Product Portfolio
  60. 8.10.5 Chia Tai-Tianqing Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Afatinib Dimaleate Value Chain Analysis
  2. 9.1.1 Afatinib Dimaleate Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Afatinib Dimaleate Production Mode & Process
  6. 9.2 Afatinib Dimaleate Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Afatinib Dimaleate Distributors
  9. 9.2.3 Afatinib Dimaleate Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst